NUCLEIC ACIDS
The fimaNAc technology provides a targeted intracellular delivery technology for nucleic acid therapeutics. Several forms of nucleic acids are widely acknowledged to have a large potential as therapeutic agents, and numerous clinical trials are underway. The therapeutic potential of such compounds is challenged by the obstacles to achieve adequate intracellular access, which the fimaNAc technology may resolve.
Most types of nucleic acids have their molecular targets inside the target cells, but nucleic acids are, by factors of their size and charge, notoriously difficult to deliver in large enough payloads inside a cell to give an effective therapeutic response.
Nucleic acids are in most cells taken up by endocytosis, but are then trapped in endosomes, constituting a barrier severely limiting the therapeutic effect that can be achieved. Thus, nucleic acids are very good candidates for enhancement by an endosomal release technology like fimaNAc , and preclinical experiments have shown that fimaNAc can give a substantial improvement in the effect of very important classes of nucleic acids (e.g. mRNA, siRNA and DNA).
fimaNAc is a collaborative programme developed through strategic partnerships with companies focusing on nucleic acid therapeutics. For more information on partnerships please visit our partnering webpage.